Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupUrologic OncologyDiseaseTesticular TumorSubgroupSeminomaICD10C62.-MeSHNeoplasms, Germ Cell and EmbryonalTesticular NeoplasmsSequenceGETUG 13TI-CE (PACL200/IFOS2), Testicular Ca, Part A (PID780) -|- TI-CE (CRBP7/ETOP400), Part B (PID781)ChemotherapyChemo-substanceBleomycinCarboplatinCisplatinEtoposideGemcitabineIfosfamideOxaliplatinPaclitaxelVinblastineChemo-substanceBleomycinCarboplatinCisplatinEtoposideGemcitabineIfosfamideOxaliplatinPaclitaxelVinblastineChemo-substanceBleomycinCarboplatinCisplatinEtoposideGemcitabineIfosfamideOxaliplatinPaclitaxelVinblastineChemo-substanceBleomycinCarboplatinCisplatinEtoposideGemcitabineIfosfamideOxaliplatinPaclitaxelVinblastineNo. Substances1235 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaPegfilgrastimPotassium chlorideNo. Substances345678910Protocol classificationTherapy classificationalternativecurrent standardIntensityDose densehigh doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleThird line Therapy phaseautologous stem cell transplantationTherapy intentioncurativecurative or palliativepalliativeRisksAnemia Hb below 8g/dlArthalgiaBleedingCardiotoxicityDiarrheaDyspneaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHemorrhageHepatotoxicityHypocalcemiaInfectionsLeukopeniaMucositisNephrotoxicityNeuropathyNeurotoxicityNeutropeniaOtotoxicityRashRenal FailureThrombocytopenia below 50 000/µl only studiesPublicationAuthorBokemeyer CBosl GCooper MACullen MFeldman DFizazi KHarstrick AKollmannsberger CLoehrer PLorch AMiller KMotzer RMulherin BPNecchi AOliver RPectasides DWilliamsDiseasefortschreitende Keimzelltumoren nach cisplatinbasiertem Regime bei schlechter Prognosefortschreitende Keimzelltumoren nach Cisplatinbasiertem Regime bei schlechter PrognoseHoden-Ca, mind. 2 cisplatinhaltige Vortherapien (inkl. ASCT), ECOG 0-1Hoden-Ca, Progress nach 2 cisplatinhaltigen Therapien oder nach ASCT, ECOG 0-2Hoden-Ca, Rezidiv nach Erstlinientherapie und Salavagetherapie mit ASCTHoden-Ca., mind. 2 Vortherapien, ECOG 0-2Hodenkarzinom, rezidiviert, Erhaltungstherapie bei CR oder PR nach HochdosistherapieHodenkarzinom, rezidiviert oder therapierefraktär, ECOG 0-2, Kreatinin-Clearance mind. 70 ml/minHodenkarzinom cisplatinrefraktär oder rezidiviert nach HochdosistherapieKeimzelltumor, Zweitliniemetastasierter, fortgeschrittener Hodentumor, nicht-seminom, IGCCCG-Prognosegruppe schlechtmetastasierter, fortgeschrittener Keimzelltumormetastasierter, fortgeschrittener Keimzelltumor, ZweitlinieMetastasierter, fortgeschrittener Keimzelltumor, Zweitlinie nach Platinkombination Nicht-Seminom, adjuvant, ErstliniePatienten mit Cisplatin refraktärem Keimzelltumor oder Rezidiv nach Hochdosistherapie mit PBSCTSeminom, Zweitlinie nach CisplatinSeminom im Stadium I, nach einer OrchidektomieStadium IIA-IIC, gute Prognose, HodentumorOriginA Medical Research Council ReportDepartment of Cancer Medicine, Institut Gustave Roussy, Villejuif, GETUG trialDepartment of Hematology, Universitätsklinikum Giessen und Marburg GmbH, Marburg, GermanyDepartment of Hematology/Oncology at University of Tuebingen Medical Center, TuebingenDepartment of Hematology and Oncology, University of Hannover Medical SchoolDepartment of Medical Oncology, London, MRC/EORTC seminoma trial collaboratorsDepartment of Medicine, Indiana University, IndianapolisDepartment of Medicine, Indiana University Medical Center, Indianapolis, USADivisions of Hematology/Oncology and Biostatistics, Indiana University Medical Center, IndianapolisEberhard Karls University, Hematology/Oncology, TübingenFondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyGenitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer CenterGenitourinary Section, Department of Medicine and the Urology Service, Memorial Sloan-Kettering Cancer Center, New York;German Testicular Cancer Study GroupHematology Oncology of Indiana, USAIndiana School of Medicine, IndianapolisInstitut Gustave Roussy, Department of Cancer Medicine, Villejuif, France, GETUG 13 trialMetaxas Memorial Cancer Hospital, Piraeus, GreeceProtocols in Revision 23 protocols foundProtocols under revision.BEP - Cisplatin 20 / Etoposide 100 / Bleomycin 30, Testicular Carcinoma, Good Prognosis. (PID771 V1.2)BEP - Cisplatin 20 / Etoposide 100 / Bleomycin 30, Testicular Carcinoma, Intermediate-High Risk (PID777 V1.2)BEP - Cisplatin 20 / Etoposide 100 / Bleomycin 30, Testicular Carcinoma, non-Seminoma, adjuvant (PID776 V1.1)Carboplatin 7, Testicular Carcinoma, Seminoma, adjuvant (PID775 V1.2)CE (Carboplatin 500 / Etoposide 500), Testicular Carcinoma (PID1574 V1.0)Cisplatin 100 / Bleomycin 25 / Ifosfamide 2, Testicular Carcinoma (PID2143 V1.0)Cisplatin 20 / Ifosfamide 1.2 / Vinblastine 0.11, Testicular Carcinoma (PID2039 V1.0)EP - Cisplatin 20 / Etoposide 100, Testicular Carcinoma (PID772 V1.1)Etoposide 50, Testicular Carcinoma (PID1577 V1.0)Gemcitabine 1000 / Paclitaxel 100, Testicular Carcinoma (PID1572 V1.0)GemOx - Gemcitabine 1000 / Oxaliplatin 130, Testicular Carcinoma (PID1571 V1.0)GIP - Gemcitabine 1000 / Ifosfamide 1.2 / Cisplatin 20, Testicular Carcinoma (PID778 V1.2)GOP - Gemcitabine 800 / Paclitaxel 80 / Oxaliplatin 130, Testicular Carcinoma (PID779 V1.1)Oxaliplatin 130, Testicular Carcinoma (PID1576 V1.0)Oxaliplatin 60, Testicular Carcinoma (PID1585 V1.0)Paclitaxel 175 / Cisplatin 20 / Etoposide 100 / Bleomycin 30 / Oxaliplatin 130, Testicular Carcinoma (PID2142 V1.0)Paclitaxel 225, Testicular Carcinoma (PID1573 V1.0)PEI - Cisplatin 20 / Etoposide 100 / Ifosfamide 1.2, testicular carcinoma (PID1284 V2.1)PEI - Cisplatin 20 / Etoposide 75 / Ifosfamide 1.2, Testicular Carcinoma (PID773 V1.2)TI-CE - Carboplatin 7 / Etoposide 400, Testicular Carcinoma, part B (PID781 V1.1)TI-CE - Paclitaxel 200 / Ifosfamide 2, Testicular Carcinoma, part A (PID780 V1.2)TIP - Paclitaxel 250 / Ifosfamide 1.5 / Cisplatin 25, Testicular Carcinoma (PID774 V1.3)TPG - Paclitaxel 80 / Gemcitabine 800 / Cisplatin 50, Testicular Carcinoma (PID1570 V1.1)
